ZITHROMAX, FIRST ONCE-DAILY FIVE-DAY ORAL ANTIBIOTIC, APPROVED BY THE FOOD AND DRUG ADMINISTRATION
ZITHROMAX, FIRST ONCE-DAILY FIVE-DAY ORAL ANTIBIOTIC, APPROVED
BY THE FOOD AND DRUG ADMINISTRATION
NEW YORK, Nov. 4 /PRNewswire/ -- Pfizer Inc (NYSE: PFE) announced today that Zithromax(A) (azithromycin), the first azalide antibiotic for the treatment of community-acquired respiratory infections, skin infections and uncomplicated genital chlamydial infections, was approved by the U.S. Food and Drug Administration.
The unique pharmacokinetic profile of Zithromax allows for effective, once-daily full-course oral antibiotic therapy in half the time required by conventional antibiotics.
"Zithromax represents a breakthrough in convenience in oral antibiotic therapy," said William C. Steere Jr., president and chief executive officer of Pfizer Inc. "We are very pleased to be able to bring this important new product to the many patients who will benefit from Zithromax."
Zithromax is taken once-daily for only five days for respiratory tract and skin infections. Most traditional therapies require 10 to 14 days of administration, usually with several daily doses.
For uncomplicated chlamydial infections, a single 1-gram oral dose of Zithromax is required, instead of two to four times a day for seven days with other drugs. This represents a breakthrough in therapy for this disease.
Medical professionals generally agree that a shorter, simpler course of antibiotic therapy improves the likelihood that patients will complete the full course of treatment.
Zithromax, the first azalide antibiotic, combines a unique pharmacokinetic profile with activity against a wide range of community- acquired infections and an excellent safety profile. As with other antibiotics, the most common side effects are related to the gastrointestinal tract.
Zithromax achieves high and sustained levels in tissue. The tissue- penetrating ability of Zithromax distinguishes it from conventional agents and results in its significantly shortened dosing regimen.
Pfizer Labs, a division of Pfizer Inc, will be responsible for marketing Zithromax. Zithromax will be available shortly.
Pfizer Inc is a diversified, research-based health care company with businesses in pharmaceuticals, hospital products, consumer products, animal health, and specialty chemicals and minerals. The company reported sales of more than $6.4 billion for 1990.
(A) -- Zithromax is a registered Pfizer trademark.
/CONTACT: A. A. Biesada, 212-573-2055, or Rick Honey, 212-573-2051, both of Pfizer/
(PFE) CO: Pfizer Inc ST: New York IN: MTC SU: PDT GK-OS -- NY020 -- 0634 11/04/91 10:16 EST